Intercept Pharmaceuticals Inc.

NASDAQ: ICPTHealthcare / Biotechnology / USA
68.75+0.9200+1.36%Vol 443 3481Y Perf -25.53%
Oct 22nd, 2019 16:00
BID68.39 ASK69.00
Open68.34 Previous Close67.83
Pre-Market68.00 After-Trading67.83
 0.17 0.25%  - -%
Target Price
141.50 
Analyst Rating
Strong Buy 1.47
Potencial %
106.12 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
60/-/-86 
Value Ranking
 —    -
Insiders Value % 3/6/12M
98/82/-71 
Growth Ranking
★★     43.75
Insiders Shares Cnt. % 3/6/12M
98/85/-58 
Income Ranking
 —    -
Market Cap (mil)2 248 
Earnings Rating
Price Range Ratio 52wk %
15.96 
Earnings Date
30th Oct 2019

Today's Price Range

67.8769.57

52wk Range

56.76131.87

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
5.57%
1 Month
-2.93%
3 Months
1.16%
6 Months
-22.04%
1 Year
-25.53%
3 Years
-50.64%
5 Years
-69.79%
10 Years
-

Name / TickerPriceChg.Chg.%
ICPT68.750.92001.36
AAPL239.94-0.5700-0.24
GOOG1 242.05-4.1000-0.33
MSFT136.32-2.1100-1.52
XOM69.100.36000.52
WFC50.630.17000.34
JNJ129.201.18000.92
FB182.24-7.5200-3.96
GE9.050.26002.96
JPM124.520.97000.79
Earnings HistoryEstimateReportedSurprise %
Q02 2019-2.51-2.289.16
Q01 2019-2.57-3.03-17.90
Q04 2018-2.42-2.97-22.73
Q03 2018-2.65-2.1817.74
Q02 2018-2.83-2.588.83
Q01 2018-3.41-3.225.57
Q04 2017-3.57-4.43-24.09
Q03 2017-3.55-2.8918.59
Earnings Per EndEstimateRevision %Trend
9/2019 QR-2.34-2.18Negative
12/2019 QR-2.36-0.43Negative
12/2019 FY-9.852.48Positive
12/2020 FY-9.58-3.34Negative
Next Report Date30th Oct 2019
Estimated EPS Next Report-2.34
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume443 348
Shares Outstanding (in ths.)32 696
Trades Count1 645
Dollar Volume25 708 761
Avg. Volume756 907
Avg. Weekly Volume341 532
Avg. Monthly Volume460 768
Avg. Quarterly Volume507 807
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
13 (76.47 %)
13 (76.47 %)
12 (70.59 %)
Moderate Buy
2 (11.76 %)
2 (11.76 %)
2 (11.76 %)
Hold
1 (5.88 %)
1 (5.88 %)
2 (11.76 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.88 %)
1 (5.88 %)
1 (5.88 %)
RatingStrong Buy
1.47
Strong Buy
1.47
Moderate Buy
1.59

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

CEO: Mark Pruzanski

Teplephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10011, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

63%38%

Bearish Bullish

28%72%

Bearish Bullish

70%30%

News